The exclusive U.S. licensing deal adds a second clinical-stage CNS ****** et to Jupiter Neurosciences' pipeline, expanding its development strategy beyond its lead Parkinson's disease program.
Jupiter Neurosciences (NASDAQ:JUNS) signed a definitive agreement for exclusive U.S. rights to ALA-002 in a transaction valued at up to $100 million.
The Jupiter Neurosciences ALA-002 license agreement transforms the company from a single-program developer into a dual clinical-stage CNS company.
ALA-002 is a patented, FDA-designated Novel Chemical Entity (NCE) designed as a non-racemic MDMA formulation for neuropsychiatric disorders.
The deal combines a modest upfront payment with milestone-based consideration tied to clinical, regulatory and commercial progress.
#clinical #deal
Jupiter Neurosciences (NASDAQ:JUNS) signed a definitive agreement for exclusive U.S. rights to ALA-002 in a transaction valued at up to $100 million.
The Jupiter Neurosciences ALA-002 license agreement transforms the company from a single-program developer into a dual clinical-stage CNS company.
ALA-002 is a patented, FDA-designated Novel Chemical Entity (NCE) designed as a non-racemic MDMA formulation for neuropsychiatric disorders.
The deal combines a modest upfront payment with milestone-based consideration tied to clinical, regulatory and commercial progress.
#clinical #deal
6 days ago
